Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.69 |
| ▸ | CDC7 | O00311 | 4/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.67 |
| ▸ | PRKACA | P17612 | 3/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.67 |
| ▸ | CDK2 | P24941 | 3/20 | 0.67 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.67 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.67 |
| ▸ | PIM1 | P11309 | 2/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | CDK8 | P49336 | 2/20 | 0.60 |
| ▸ | AXL | P30530 | 2/20 | 0.60 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.59 |
| ▸ | JAK2 | O60674 | 3/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.59 |
| ▸ | CLK2 | P49760 | 3/20 | 0.59 |
| ▸ | JAK3 | P52333 | 3/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858985 | 0.96 | CAMKK2 (0.70) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL20846288 | 0.91 | CAMKK2 (0.60) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL18418494 | 0.89 | CDC7 (0.71) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL857678 | 0.87 | IKBKE (0.64) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL5618155 | 0.86 | TGFBR1 (0.71) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL859052 | 0.86 | CAMKK2 (0.62) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL29869901 | 0.86 | CDC7 (0.68) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL856823 | 0.86 | CDC7 (0.68) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL858766 | 0.84 | CAMKK2 (0.64) | CAMKK2CDC7MAP4K4CLK4PRKACA | |
| SCHEMBL5907880 | 0.84 | CAMKK2 (0.64) | CAMKK2CDC7MAP4K4CLK4PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023168686-A1 | SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-14 | — | — | WO | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1771446-A2 | AZAINDOLE INHIBITORS OF MTP AND APOB | Merck Patent GmbH (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006010423-A2 | AZAINDOLE INHIBITORS OF MTP AND APOB | MERCK PATENT GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | CAMKK2 597/4885CDC7 4350/4885MAP4K4 2491/4885 |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | CAMKK2 1116/4885CDC7 4496/4885MAP4K4 2372/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | CAMKK2 171/4885CDC7 864/4885MAP4K4 60/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | CAMKK2 2871/4885CDC7 2430/4885MAP4K4 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.